Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Use of CyberKnife II to Treat Tumors in Trunk of the Body Approved: Accuray
September 8, 2008
- BUSINESS NEWS IN BRIEF
September 8, 2008
- Terumo's DuraHeart Implanted in 1st Patient in US
September 8, 2008
- Yamato Expects Profits from Generics Delivery Service in 3 Years
September 8, 2008
- BD Enters Market for Cytodiagnostic Systems for Cervical Cancer
September 8, 2008
- Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
September 8, 2008
- Vascular Embolization Set for AVM Recommended for Approval
September 8, 2008
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
September 8, 2008
- R&D NEWS IN BRIEF
September 8, 2008
- Astellas Aims at Top Market Share in Japan
September 8, 2008
- 4 Healthcare Clusters to Focus on 4 Fields
September 8, 2008
- Prevent Recurrence of Stroke: Prof. Hasegawa
September 8, 2008
- Recommending Hp Eradication in All Infected Persons: JSHR
September 8, 2008
- Takara Bio to Start Cancer Cell Immunotherapy in Kyoto Clinic
September 8, 2008
- Takeda Suspends Development of Hematide for Chemotherapy-Induced Cancerous Anemia
September 8, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 8, 2008
- CGI to Stop PIII Trial on Prostate Cancer Vaccine Licensed to Takeda
September 8, 2008
- METI Demands \609.3 Bil. to Promote Science & Technology
September 8, 2008
- OPINION
September 1, 2008
- Nippon Kayaku to Support Growth by Proprietary Micellar Technology
September 1, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…